and is frequently present in patients affected by T2DM, which in turn appears to accelerate the progression of atherosclerotic lesions towards CVD. Several studies have established that there is a 1% to 1% relation- ship between CVD event reduction and reduction of low-density lipo- protein cholesterol (LDL-C) through specific lipid-lowering therapy [11].